A combined treatment of silybin and regorafenib induced, in a panel of human colon cancer cell lines with distinct mutations in the KRAS, NRAS, BRAF, and PIK3CA genes, synergistic anti-proliferative and apoptotic effects via the inhibition of the PI3K/AKT/mTOR pathway and the production of ROS within cells [82]. This evidence concerns the gene PIK3CA and malignant colon neoplasm.